Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Autelitano, Dominic J ^a   Raineri, Linda ^a   Knight, Kate ^a   Bannister, Kelly ^a   Rice, Gregory E ^b  

^a HealthLinx Ltd   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Diagnostic; Multianalyte; Ovarian cancer; Tumour markers

Indexed keywords

C REACTIVE PROTEIN; CA 125 ANTIGEN; INTERLEUKIN 6; INTERLEUKIN 8; SERUM AMYLOID A; TUMOR MARKER;

ADULT; ARTICLE; CANCER DIAGNOSIS; CASE CONTROL STUDY; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; FEMALE; HUMAN; IN VITRO DIAGNOSTIC MULTIVARIATE INDEX ASSAY; INTEGRATED DISCRIMINATION IMPROVEMENT; MAJOR CLINICAL STUDY; NET RECLASSIFICATION IMPROVEMENT; OVARY CANCER; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STATISTICAL ANALYSIS; ALGORITHM; AREA UNDER THE CURVE; BIOASSAY; BLOOD; METHODOLOGY; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARY TUMOR; RECEIVER OPERATING CHARACTERISTIC; STANDARD;

ALGORITHMS; AREA UNDER CURVE; BIOLOGICAL ASSAY; CA-125 ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVARIAN NEOPLASMS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 84857976315     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-45     Document Type: Article

References (35)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917. 10.1002/ijc.25516, 21351269.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
3. Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004, 3:355-366. 10.1074/mcp.R400006-MCP200, 14764655.
4. Jacobs I, Bast RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989, 4:1-12.
5. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990, 97:922-929. 10.1111/j.1471-0528.1990.tb02448.x, 2223684.
6. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J, Bast RC. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 2005, 99:267-277. 10.1016/j.ygyno.2005.06.040, 16061277.
7. Amonkar SD, Bertenshaw GP, Chen TH, Bergstrom KJ, Zhao J, Seshaiah P, Yip P, Mansfield BC. Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoS One 2009, 4:e4599. 10.1371/journal.pone.0004599, 2643010, 19240799.
8. Edgell T, Martin-Roussety G, Barker G, Autelitano DJ, Allen D, Grant P, Rice GE. Phase II biomarker trial of a multimarker diagnostic for ovarian cancer. J Cancer Res Clin Oncol 2010, 136:1079-1088. 10.1007/s00432-009-0755-5, 2874491, 20082099.
9. Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE. Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:981-987. 10.1158/1055-9965.EPI-04-0404, 15824174.
10. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008, 108:402-408. 10.1016/j.ygyno.2007.10.017, 18061248.
11. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC. Lokshin A: Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol 2010, 117:440-445. 10.1016/j.ygyno.2010.02.005, 2873171, 20334903.
12. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008, 14:1065-1072. 10.1158/1078-0432.CCR-07-1569, 18258665.
13. Zhang Z, Bast RC, Yu Y, Li J, Sokoll LJ, Rai AJ, Rosenzweig JM, Cameron B, Wang YY, Meng XY, et al. Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res 2004, 64:5882-5890. 10.1158/0008-5472.CAN-04-0746, 15313933.
14. Ware Miller R, Smith A, Desimone CP, Seamon L, Goodrich S, Podzielinski I, Sokoll L, van Nagell JR, Zhang Z, Ueland FR. Performance of the american college of obstetricians and gynecologists' ovarian tumor referral guidelines with a multivariate index assay. Obstet Gynecol 2011, 117:1298-1306. 10.1097/AOG.0b013e31821b1d80, 21555961.
15. Pencina MJ, D'Agostino RB, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008, 27:157-172. discussion 207-112, 10.1002/sim.2929, 17569110.
16. Pencina MJ, D'Agostino RB, Vasan RS. Statistical methods for assessment of added usefulness of new biomarkers. Clin Chem Lab Med 2010, 48:1703-1711. 3155999, 20716010.
17. Cook NR. Comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10.1002/sim.2929). Stat Med 2008, 27:191-195. 10.1002/sim.2987, 17671959.
18. Kerr KF, McClelland RL, Brown ER, Lumley T. Evaluating the incremental value of new biomarkers with integrated discrimination improvement. Am J Epidemiol 2011, 174:364-374. 10.1093/aje/kwr086, 21673124.
19. Pencina MJ, D'Agostino RB. Steyerberg EW: Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011, 30:11-21. 10.1002/sim.4085, 21204120.
20. Stone M. Cross-validatory choice and assessment of statistical predictions. J Royal Statistical Soc 1974, 36:111-147.
21. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982, 143:29-36.
22. Efron B. Discussion: Jacknife, Bootstrap and other resampling methods in regression analysis. Ann Statist 1986, 14:1301-1304.
23. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol 2010, 28:2159-2166. 10.1200/JCO.2008.19.2484, 2860434, 20368574.
24. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, Kurman RJ, Bast RC, Skates SJ. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010, 203:228. e221-226.
25. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, Gajewski W, Kurman R, Bast RC, Skates SJ. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol 2009, 112:40-46. 10.1016/j.ygyno.2008.08.031, 18851871.
26. Zhu CS, Pinsky PF, Cramer DW, Ransohoff DF, Hartge P, Pfeiffer RM, Urban N, Mor G, Bast RC, Moore LE, et al. A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer. Cancer Prev Res (Phila) 2011, 4:375-383.
27. Bast RC. Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC: Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 1981, 68:1331-1337. 10.1172/JCI110380, 370929, 7028788.
28. Hefler LA, Concin N, Hofstetter G, Marth C, Mustea A, Sehouli J, Zeillinger R, Leipold H, Lass H, Grimm C, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res 2008, 14:710-714. 10.1158/1078-0432.CCR-07-1044, 18245530.
29. Berek JS, Chung C, Kaldi K, Watson JM, Knox RM, Martinez-Maza O. Serum interleukin-6 levels correlate with disease status in patients with epithelial ovarian cancer. Am J Obstet Gynecol 1991, 164:1038-1042. discussion 1042-1033.
30. Merritt WM, Lin YG, Spannuth WA, Fletcher MS, Kamat AA, Han LY, Landen CN, Jennings N, De Geest K, Langley RR, et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008, 100:359-372. 10.1093/jnci/djn024, 2770251, 18314475.
31. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzal E, Kainz C. Serum evaluation of interleukin 6 in ovarian cancer patients. Gynecol Oncol 1997, 66:27-30. 10.1006/gyno.1997.4726, 9234916.
32. Urieli-Shoval S, Finci-Yeheskel Z, Dishon S, Galinsky D, Linke RP, Ariel I, Levin M, Ben-Shachar I, Prus D. Expression of serum amyloid a in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J Histochem Cytochem 2010, 58:1015-1023. 10.1369/jhc.2010.956821, 2958134, 20713982.
33. Watson JM, Sensintaffar JL, Berek JS, Martinez-Maza O. Constitutive production of interleukin 6 by ovarian cancer cell lines and by primary ovarian tumor cultures. Cancer Res 1990, 50:6959-6965.
34. Colomiere M, Ward AC, Riley C, Trenerry MK, Cameron-Smith D, Findlay J, Ackland L, Ahmed N. Cross talk of signals between EGFR and IL-6R through JAK2/STAT3 mediate epithelial-mesenchymal transition in ovarian carcinomas. Br J Cancer 2009, 100:134-144. 10.1038/sj.bjc.6604794, 2634691, 19088723.
35. Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, et al. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 2010, 285:35462-35470. 10.1074/jbc.M110.109579, 2975170, 20826776.